The detection of 2-AAA is a simple test that can be done from a blood sample. The discovery was based on human sampling from the Framingham Heart Study that tracked potentially diabetic people and those that had no potential for diabetes for 12 years. The validity of 2-AAA as a biomarker for diabetes was confirmed in mouse studies that compared fasting plasma glucose levels in mice that ate a high fat diet with mice that ate a regular diet. 2-AAA administered to mice and humans increased insulin production. The researchers found no correlation with and no interference from any other known biomarkers for diabetes.
For the original version including any supplementary images or video, visit http://www.examiner.com/article/discovery-marker-predicts-diabetes-12-years-before-disease-begins
Biomarker that can predict diabetes risk identified
The researchers also conducted laboratory studies to understand why this biomarker is elevated so well in advance of the onset of diabetes. They found that giving 2-AAA to mice alters the way they metabolise glucose. These molecules seem to influence the function of the pancreas, which is responsible for making insulin, the hormone that tells the body to take up blood sugar. “2-AAA appears to be more than a passive marker.
For the original version including any supplementary images or video, visit http://www.indianexpress.com/news/biomarker-that-can-predict-diabetes-risk-identified/1170329/
Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
For more information, visit http://www.lillydiabetes.com . About Eli Lilly and Company Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers through medicines and information for some of the world’s most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com . P-LLY This press release contains forward-looking statements about two investigational compounds, dulaglutide and novel basal insulin LY2605541, which are currently in development for the treatment of diabetes.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/lilly-present-data-across-diabetes-120000330.html